Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
Cognitive Dysfunction in Parkinson's Disease 10-0771
This research study plans to use simultaneous brain scans and memory tasks to see if stimulating certain areas of the brain improves thinking and memory. This is not a treatment study
Healthy males over 50 with Parkinson's disease on stable doses of medication and have no metal in the body (dental work may be ok).
PI: Kluger, Benzi
  • 303-724-5973
  • isabelle.buard@ucdenver.edu
EFFECTS OF TESTOSTERONE THERAPY IN YOUNG ADOLESCENTS WITH KLINEFELTER SNDROME (47.XXY) 11-0874
This study will study the effects of testosterone therapy on behavior, mood, problem solving, attention span, and motor skills in adolescent males with Klinefelter syndrome in early puberty. During this period in early puberty there is a lot of variability in how and when doctors start testosterone therapy. This study will evaluate if there are benefits to starting testosterone therapy in early puberty.
Participants with Klinefelter syndrome in early puberty (around age 10-15).
PI: Tartaglia, Nicole
  • 720-777-8361
  • susan.howell@childrenscolorado.org
Are you interested in a supervised weight loss intervention? 12-1352
Volunteers needed for a research weight loss study to examine the neuronal and behavioral changes that occur with different weight loss interventions.
- 21-65 years old - Non- smoker - Non- Diabetic - Exercise no more than 1 time a week - Maintained your current weight for the last 6 months - Have a body mass index of 30 -40 (check it out at http://nhlbisupport.com/bmi/
PI: Cornier, Marc
  • 303-724-9024
  • mailto:allison.hild@ucdenver.edu
Are you a Parkinson's patient not requiring symptomatic treatment with drugs? 13-2808
This research study explores the effects of an FDA approved drug on Parkinson's disease.
Recently diagnosed Parkinson's patients who are not taking any drugs for symptomatic relief or are willing to go off drugs for the duration of the study with neurologist approval. We are also looking for healthy control participants.
PI: Freed, Curt
  • 303-724-6015
  • Mary.wang@ucdenver.edu
The Health Influences in Puberty "HIP" study 07-0988
Research study about puberty and risk for type 2 diabetes
Healthy boy between 11 and 13 years of age Healthy girl between 9 and 11 years of age
PI: Kelsey, Megan
  • 720-777-6148
  • allison.hilkin@childrenscolorado.org
Volunteers with Alzheimer’s Disease Needed for Memory Study 12-1273
To examine the safety and efficacy of the study drug, Sargramostim (Leukine®), on memory in adults with Mild-to-Moderate Alzheimer’s Disease.
1. Age 55 to 85 years; 2. Should have a mild-to-moderate Alzheimer's Disease diagnosis (Mini-Mental State Examination 10-26 inclusive); 3. If on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona); 4. Stable on all other medications for at least 30 days prior to screen; 5. Should be fluent in English; 6. Should be physically able to participate by medical history, clinical exam and tests; 7. Should have a study partner to accompany them to scheduled visits.
PI: Potter, Huntington
  • 303-724-2997
  • joseph.daniels@ucdenver.edu
Healthy Hispanic Female Adults Needed 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Do you have high blood pressure? 13-3174
Researchers at the University of Colorado Hospital are conducting a research study to help predict if blood pressure medications will work for you.
Subject must be between 30 and 75 years of age and have a diagnosis of uncontrolled hypertension (high blood pressure).  As part of the study, you may be eligible for free medication and free clinic visits to check your blood pressure
PI: Monte, Andrew
  • 303-724-7871
  • hanna.flaten@ucdenver.edu
T•A•C•I•T - Therapy After Cochlear Implants Using Telemedicine 12-1103
This research plans to learn more about the use of telemedicine as a means of providing therapy to children who have a cochlear implant(s). While Auditory-Verbal Therapy has typically been delivered in person, many people are starting to access therapy over the internet. We are conducting this research to determine if the outcomes of therapy are the same when AVT is delivered in person and via telemedicine.
The TA•C•I•T team is looking for children ages 6 mos.-6 yrs. old who were implanted with cochlear implant(s) before age  3 ½..  Each child will spend nine months in both the in-person and telemedicine condition. The therapist will remain the same throughout the study. Total participation will last 18 months. The child will be tested three times: once when the study starts, and every nine months after that. A qualified study team member will administer speech, listening, and language tests to the child. They will also receive tests to identify how well their auditory area of the brain is developing.
PI: Grigsby, Jim
  • 303.556.5804
  • tacit@ucdenver.edu
Participants with Chronic Kidney Disease Needed for a Research Study about Phosphate 13-0328
We are looking for men and women to participate in a research study examining whether lowering blood levels of phosphate will improve blood vessel function.
We need men and women who:  -are age 40-79 years old; women must be post-menopausal;  -have chronic kidney disease stage 3b or 4 (estimated GFR 15-45 ml/min);  -are not taking phosphate binders;  -do not have high blood phosphate (>5.5 mg/dL).
PI: Jovanovich, Anna
  • 303-724-7790
  • mikaela.malaczewski@ucdenver.edu
Are you interested in a research study of a new investigational birth control patch? 14-1868
We are recruiting women to join a large clinical research study of a contraceptive patch. The patch contains the same type of hormones that are in many birth control pills. The patch is designed to be flexible and is applied onto the skin, just once a week.
• Be sexually active at least once a month • Need to use birth control • Not wish to become pregnant for at least 1 year • Be able to use the patch as your only form of birth control for at least 1 year.
PI: Teal, Stephanie
  • 303-724-5559
  • christina.gavito@ucdenver.edu
ESS-NSPAS Study 14-1808
Bayer HealthCare is sponsoring a medical research study to look at the effectiveness of Essure after having a procedure (NovaSure) that decreases your heavy menstrual bleeding. Both Essure and NovaSure are approved by the FDA. This study is enrolling patients now and you may qualify to participate.
Are you currently using the Essure method of contraception? Are your periods heavy, frequent or prolonged? One important prerequisite is - you must have had a successful Essure placement AND be willing to undergo a NovaSure endometrial ablation, a treatment option for heavy menstrual bleeding (menorrhagia).
PI: Tocce, Kristina
  • 303-724-5559
  • christina.gavito@ucdenver.edu
Do you suffer from scalp psoriasis? 14-1577
We are researching a new drug that may help with your scalp psoriasis. We invite you to participate in a research study testing a novel therapy in scalp psoriasis.
To qualify for this study, you must be an adult 18 years of age or older, and you must be diagnosed with moderate to severe scalp psoriasis (for at least six months).
PI: Armstrong, April
  • 720-848-3607
  • psoriasiscolorado@ucdenver.edu
Would you like to volunteer for a research study? 14-1561
Your participation in this study will help the researcher to understand more about cervical cancer prevention among Hispanic women who have Mexican and Mexican-American cultural values.
English speaking female, who was born, and currently lives, in the U.S., has had a pap smear, is between the ages 21-50 years old, and self-identifies as Mexican or Mexican-American.
PI: Warren, Dulce
  • (720) 445-5623
  • dulce.warren@ucdenver.edu
Volunteers with Chronic Kidney Disease needed for a Uric Acid Lowering Research Study 10-0625
To understand the effect of lowering serum uric acid levels on vascular function in individuals with CKD by comparing Allopurinol therapy and a placebo.
Persons 18+ with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates  between 30-60 mL/min/1.73m2
PI: Jalal, Diana
  • 303-724-2275
  • Emily.decker@ucdenver.edu
Research Study: "Anxiety Risk in Teens" 12-0424
To learn more about risk factors for anxiety in adolescents with cyclic vomiting syndrome.
Adolescents 13-18 who have been diagnosed with either an anxiety disorder or cyclic vomiting syndrome
PI: Tarbell, Sally
  • 720-777-6255
  • sally.tarbell@ucdenver.edu
Are you interested in learning about how your breast milk helps your baby grow? 12-0629
To find out how maternal size and diabetes status affect her breast milk To find out what unique parts of breast milk may affect how infants grow. To learn how to ensure infants receive the best nutrition possible
Women 20-35 who are at least 28 weeks into their pregnancy and planning on exclusively breastfeeding their infant for at least 4 months and delivering at University of Colorado Hospital.
PI: Krebs, Nancy
  • 303-724-3972
  • catherine.chartier-logan@ucdenver.edu
Free Family Therapy for Youth with Mood Problems 11-1048
Helping youth and their families understand and cope with mood swings, develop plans for preventing moods from getting worse, communicate more effectively and solve family problems
  • Youth between 9-17 who has recently had significant mood swings, has at least one parent with bipolar disorder and does not abuse alcohol or substances. 
  • Must agree not to participate in family therapy with another provider for the first year.
PI: Schneck, Christopher
  • 303-492-1668
  • Anna.Frye@colorado.edu
Genital Herpes? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of genital herpes.  1-2 study visits for blood draws over the course of 3 months.
  • 18+ years of age
  • Have developed an outbreak of genital herpes within the last 10 days.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
Pregnant Participants Needed: 13-3019
Pregnant women are invited to participate in a research study which plans to learn about antibody (substance produced by the body to fight disease) levels in mothers and infants whose mothers have received the GBS vaccine between 24-34 6/7 weeks of their current pregnancy.  the study will also look at antibody levels in mother's breast milk.
  • Healthy pregnant woman 18-40 years of age 24 0/7 through 34 6/7 weeks pregnant 
  • Planning to breastfeed for at least 90 days after delivery 
  • Plan to deliver at University of Colorado Hospital
PI: Gibbs MD, Ronald
  • 303-724-2005
  • sarah.schwartz@ucdenver.edu
Healthy Volunteers Needed 13-3002
The Department of Neurology is looking for healthy volunteers to participate in a research study examining blinking and spasms in people with Blepharospam compared to healthy controls
  • Between the ages of 50-80
  • Must not have any metal in your body
  • In good general health
PI: Berman, Brian
  • 303-724-5865
  • erika.shelton@ucdenver.edu
Healthy Volunteers Needed for a research study of drug levels in blood and hair. 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
  • Subject is age 18 to 50 years 
  • Subject is ambulatory 
  • Subject is able to comply with directly observed dosing procedures, including use of audio-visual streaming technology 
  • Subject is able to give informed consent 
  • Subject has a minimum scalp hair length of 2 cm in the occipital region. 
  • Subject is NOT pregnant, planning to become pregnant, or currently breastfeeding
  • Subject is low risk for HIV-1 infection 
  • Subject does NOT have any active psychiatric illness(es), social condition(s), or alcohol/drug abuse 
  • Subject does NOT have history of non-traumatic, pathologic bone fractures 
  • Subject does NOT have any medical conditions that alter red blood cell kinetics 
  • Subject does NOT have any uncontrolled medical conditions that would interfere with the study conditions
  • Subject does NOT have contraindicated concomitant medications
PI: Anderson, Peter
  • 3037248296
  • kayla.bushman@ucdenver.edu
Research Participants Needed 14-0770
We are looking for healthy participants to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria:
  1. 50-85 years of age.
  2. Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking).
  3. No neurological, vascular or cardiac problems that limit function.
  4. Body mass index.
PI: Christiansen, Cory
  • 303*724-9590
  • Amanda.murray@ucdenver.edu
Thinking About Starting a New Physical Activity Program? 14-0275
This study will examine psychosocial predictors of physical activity. Participants will become members of the Anschutz Health and Wellness Center and will complete a variety of questionnaires and two fitness assessments over 12 weeks. Most of the questionnaires are completed online.
  • 30-89 years of age
  • Able to read and understand English
  • Not participating in regular physical activity for the past 3 months
  • Joining the Anschutz Health and Wellness Center
  • No physical contraindications to physical activity
  • No existing diagnoses of cardiovascular disease
  • Not pregnant.
PI: Hooker, Stephanie
  • 303-724-8228
  • stephanie.hooker@ucdenver.edu
The Role of Gut Bacteria in the Development of Type 1 Diabetes 11-1144
The goal of the research is to better understand the role bacteria that live in the intestine in the development of type 1 diabetes
  • Patients diagnosed with type 1 diabetes in the last 6 months 
  • Subjects with islet autoantibodies 
  • Subjects who do not have islet antibodies and are first-degree relatives of patients with diabetes or subjects with islet antibodies
  • 1-45 years of age
PI: Zipris, Danny
  • 303-724-6820 or 303-724-6821
  • aimon.alkanani@ucdenver.edu or james.needell@ucdenver.edu
Tell us your story... 12-1432
We are conducting a research study to learn more about the reproductive health of Latinas.
Female 29-43 years old Born in the U.S. Have both parents born in the U.S. Have a grandparent or great grandparent born in Mexico
PI: Coleman-Minahan, Kate
  • 303-916-6567
  • kate.coleman-minahan@ucdenver.edu
Do you have Parkinson's Disease? 11-1237
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
PI: Schenkman, Margaret
  • 720-848-6376
  • Toby.Wellington@ucdenver.edu
Do you have Atopic Dermatitis (Eczema)? HS-2581
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
PI: Leung, Donald
  • 303-398-1409
  • taylorp@njhealth.org
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease. 10-0644
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
PI: Rasouli, Neda
  • 303-399-8020 X2059
  • chantal.underkofler@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 10-1393
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
PI: Schauer, Irene
  • 720-848-6688
  • Katie.Rogers@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 564.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 19, items 1 to 30 of 564.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James14-0383
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Sponsor Protocol No. M12-914 WIRB Protocol No. 20141072
Borges, Virginia14-0799
PROspective Study of the IMPACT of Decipher® Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions following Radical Prostatectomy [PRO-IMPACT] Sponsor Protocol No. CU004 WIRB Protocol No. 20142208
Maroni, Paul14-0910
A Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Sponsor Protocol No. CD-IA-MEDI-551-1155 WIRB Protocol No. 20142285
Bennett, Jeffrey14-0926
CEP292- A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 hours (7days) of Use. Sponsor Protocol No. CEP292/Z25/B. WIRB Protocol No. 20140632
Slover, Robert14-1039
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RPC4046 IN ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS. Sponsor Protocol No. RPC02-201. WIRB Protocol No. 20140555
Menard-Katcher, Paul14-1285
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS). Sponsor Protocol No. 101MS409. WIRB Protocol No. 20141062
Alvarez, Enrique14-1295
A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo. Sponsor Protocol No. PM1116197. WIRB Protocol No. 20141040
Krantz, Mori14-1331
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy Sponsor Protocol No. 13-005 WIRB Protocol No. 20141141
Halbower, Ann14-1333
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects with Chronic Rhinosinusitis with Nasal Polyps. Sponsor Protocol No. 20110236. WIRB Protocol No. 20150667
Kingdom, Todd14-1371
An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 following a Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment Sponsor Protocol No. D5160C00008 WIRB Protocol No. 20142209
O'Bryant, Cindy14-1390
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFET Sponsor Protocol No. RPC02-201 WIRB Protocol No. 20140555
Fleischer, David14-1399
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study Sponsor Protocol No. 191622-111 WIRB Protocol No. 20132162
Biffl, Susan14-1404
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study Protocol No. 191622-112 WIRB Protocol No. 20132135
Biffl, Susan14-1405
An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered with Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Sponsor Protocol No. M14-224. WIRB Protocol No. 20142269
Everson, Greg14-1435
A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma. Sponsor Protocol No. SAS115358. WIRB Protocol No. 20111924
Anderson, William14-1445
A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA Sponsor Protocol No. GO29365 WIRB Protocol No. 20141475
Gutman, Jonathan14-1455
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects with Bone Metastases Treated with Hormonal Treatment Background Therapy Sponsor Protocol No. BAY 88-8223 / 16298 WIRB Protocol No. 20150791
Fisher, Christine14-1465
Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors. Sponsor Protocol No. GO29313. WIRB Protocol No. 20141118
Camidge, David14-1476
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer. Sponsor Protocol No. M14-361. WIRB Protocol No. 20142537
Camidge, David14-1489
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II). Sponsor Protocol No. M14-868. WIRB Protocol No. 20141974
Everson, Greg14-1494
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection. Sponsor Protocol No. 2014-01. WIRB Protocol No. 20141261
Freeman, Stephen14-1538
A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS Sponsor Protocol No. GO29146 WIRB Protocol No. 20140268
Weekes, Colin14-1551
TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) Sponsor Protocol No. CO-1686-022 WIRB Protocol No. 20142085
Camidge, David14-1569
An Open-Label, Multi-Center, 48-Week Study with a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy. Sponsor Protocol No. 4658-301-a1. WIRB Protocol No. 20141230
Parsons, Julie14-1629
Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma Sponsor Protocol No. PIN-PHO1201 WIRB Protocol No. 20140456
Shah, Raj14-1650
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease. Sponsor Protocol No. RECD3125. WIRB Protocol No. 20141667
Gerich, Mark14-1659
A Comparison of Soy Protein versus Soy-Dairy Protein-blend Containing Foods in the Colorado Diet for Weight loss and Maintenance. WIRB Protocol No. 20150081
Hill, James14-1666
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy Sponsor Protocol No. ALDOXORUBICIN-P2-SCLC-01 WIRB Protocol No. 20141373
Doebele, Robert14-1673


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more